Cargando…

Role of Olaparib in the Management of Metastatic Castration-Resistant Prostate Cancer: A Japanese Clinician’s Perspective

Several studies have identified various targetable genomic alterations in prostate cancer, which accumulate during carcinogenesis and cancer progression. Genomic alterations in genes involved in DNA damage repair by homologous recombination repair may predict increased sensitivity to poly-ADP ribose...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matsumoto, Takashi, Shiota, Masaki, Blas, Leandro, Eto, Masatoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9373991/ https://www.ncbi.nlm.nih.gov/pubmed/35967752 http://dx.doi.org/10.2147/CMAR.S326114

Ejemplares similares

Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with castration-resistant prostate cancer
por: Chikamatsu, Sotaro, et al.
Publicado: (2022)

Current Status and Future Perspective on the Management of Lymph Node-Positive Prostate Cancer after Radical Prostatectomy
por: Shiota, Masaki, et al.
Publicado: (2022)

Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer
por: Yamada, Shigetomo, et al.
Publicado: (2022)

Conceptual assessment of HRQOL among Japanese non‐metastatic castration‐resistant prostate cancer (nmCRPC) patients
por: Nishimura, Kazuo, et al.
Publicado: (2022)

Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer
por: Wallis, Christopher J. D., et al.
Publicado: (2021)

Active Surveillance in Intermediate-Risk Prostate Cancer: A Review of the Current Data
por: Blas, Leandro, et al.
Publicado: (2022)

External Validation of a Prognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Patients Receiving Post-Docetaxel Second-Line Chemotherapy
por: Blas, Leandro, et al.
Publicado: (2022)

Anticancer Effect of Second-line Treatment for Castration-Resistant Prostate Cancer Following First-line Treatment with Androgen Receptor Pathway Inhibitors
por: Matsumoto, Takashi, et al.
Publicado: (2021)

Cost-Effectiveness of Genomic Test-Directed Olaparib for Metastatic Castration-Resistant Prostate Cancer
por: Su, Dan, et al.
Publicado: (2021)

Contextualizing Olaparib and Abiraterone in the Current Treatment Landscape for Metastatic Castration-resistant Prostate Cancer
por: Fallara, Giuseppe, et al.
Publicado: (2023)

Efficacy and safety of cabazitaxel therapy in elderly (≥75 years) patients with castration-resistant prostate cancer: A multiinstitutional study
por: Matsumoto, Takashi, et al.
Publicado: (2021)

Comparative efficacy of olaparib in combination with or without novel antiandrogens for treating metastatic castration-resistant prostate cancer
por: Chen, Xiangyu, et al.
Publicado: (2023)

Validation of user-friendly models predicting extracapsular extension in prostate cancer patients
por: Blas, Leandro, et al.
Publicado: (2023)

Long‐term outcomes of androgen deprivation therapy in prostate cancer among Japanese men over 80 years old
por: Blas, Leandro, et al.
Publicado: (2021)

Gene amplification of YB‐1 in castration‐resistant prostate cancer in association with aberrant androgen receptor expression
por: Shiota, Masaki, et al.
Publicado: (2020)

Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report
por: Ma, Yi, et al.
Publicado: (2018)

Expression of MUS81 Mediates the Sensitivity of Castration-Resistant Prostate Cancer to Olaparib
por: Gong, Lifeng, et al.
Publicado: (2022)

Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
por: Karzai, Fatima, et al.
Publicado: (2018)

Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection
por: LeVee, Alexis, et al.
Publicado: (2021)

Cost-effectiveness of olaparib, a PARP inhibitor, for patients with metastatic castration-resistant prostate cancer in China and United States
por: Xu, Chenxia, et al.
Publicado: (2022)

Treatment Strategies for Metastatic Castration-Sensitive Prostate Cancer: From “All-Comers” to “Personalized” Approach
por: Harada, Kenichi, et al.
Publicado: (2021)

Olaparib-Induced Purpuric Drug Eruption in a Patient with Castration-Resistant Prostate Cancer
por: Sekine, Mana, et al.
Publicado: (2023)

Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection [Corrigendum]
Publicado: (2021)

Olaparib outcomes in metastatic castration-resistant prostate cancer: First real-world experience in safety and efficacy from the Chinese mainland
por: Pan, Jian, et al.
Publicado: (2022)

Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984
por: Kim, Joseph W., et al.
Publicado: (2023)

Addition of Olaparib to the New Hormonal Agent Regimen for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
por: Warli, Syah Mirsya, et al.
Publicado: (2023)

An oral first‐in‐class small molecule RSK inhibitor suppresses AR variants and tumor growth in prostate cancer
por: Ushijima, Miho, et al.
Publicado: (2022)

Differential Impact of TGFB1 Variation by Metastatic Status in Androgen-Deprivation Therapy for Prostate Cancer
por: Shiota, Masaki, et al.
Publicado: (2021)

Taxane Chemotherapy for Hormone-Naïve Prostate Cancer with Its Expanding Role as Breakthrough Strategy
por: Shiota, Masaki, et al.
Publicado: (2016)

The Role of Nuclear Receptors in Prostate Cancer
por: Shiota, Masaki, et al.
Publicado: (2019)

Prognostic factors in Japanese men with high-Gleason metastatic castration-resistant prostate cancer
por: Nishimoto, Mitsuhisa, et al.
Publicado: (2022)

FGFR1, a novel biomarker for metastatic castration-resistant prostate cancer?
por: Gallo, Leandro H.
Publicado: (2021)

Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer
por: Carr, T. Hedley, et al.
Publicado: (2021)

Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA
por: Matsubara, Nobuaki, et al.
Publicado: (2023)

Efficacy and safety of olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis of randomized controlled trials
por: Luo, Zhanyang, et al.
Publicado: (2023)

Phase II Trial Evaluating Olaparib Maintenance in Patients with Metastatic Castration-Resistant Prostate Cancer Responsive or Stabilized on Docetaxel Treatment: SOGUG-IMANOL Study
por: Juan Fita, María José, et al.
Publicado: (2023)

Prognostic significance of diabetes mellitus and dyslipidemia in men receiving androgen-deprivation therapy for metastatic prostate cancer
por: Hirata, Yu, et al.
Publicado: (2019)

Unmet needs in non-metastatic castration-resistant prostate cancer from the Japanese patient perspective: a discrete choice experiment
por: Uemura, Hiroji, et al.
Publicado: (2021)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

Relationship between body composition and hormone sensitivity for androgen deprivation therapy in patients with metastatic prostate cancer
por: Kashiwagi, Eiji, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2pipccdnjrpd5eb017bmk3drqs